[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"failed-back-surgery-syndrome-fbss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:failed-back-surgery-syndrome-fbss":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100651571","phase-4-success-rates-and-safety-of-steroid-injections-in-managing-spinal-and-sacro-iliac-pain-cortisone-injection-spine-study-100651571",false,"NCT07762170","Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Injection Spine Study)","Success Rates and Safety in Managing Spinal and Sacro-Iliac Pain: A Critical Analysis","CORTISS","Inclusion Criteria:\n\n* \\>18 years of age;\n* Diagnosis of lumbar, cervical, or thoracic pain with various etiologies;\n* Eligibility to receive steroid injections for back pain, including epidural, facet joints, or SIJ injections, or other injections (e.g., local anesthetics);\n* Being willing and able to provide NRS pain ratings and PROMIS functionality ratings before the intervention, and the same scores plus IPR, fIPR, and PGIC at various follow-up points after the intervention;\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of dementia, Parkinson's disease or other cognitive impairments;\n* Congenital or acquired polyneuropathy;\n* Back surgery in the month before injection treatment or planned surgery in the subsequent 3 months;\n* Any clinically significant acute or chronic medical condition that in the judgment of Investigator may preclude injection in the epidural space or compromise patient safety, limit patient's ability to complete the study, and\u002For compromise the objectives of the study;\n* Participation in any other competing clinical study within 3 months prior to screening and during the study period.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aims to analyze the efficacy and safety of different kinds of steroid injections for back pain, comparing different steroids, dosages, locations (epidural, facet joints, nerve blocks), and also the difference between injections with steroids and local anesthetics, to optimize this treatment that is currently not standardized. The investigators will compare retrospectively and prospectively the efficacy of different injections in the same patients, using mainly a parameter called integral of pain relief, which combines the percentage of pain relief provided by a treatment and its duration over time, as well as improvements in functionality.",[27,28,29,30,31,32,33,34,35],"Back Pain Lower Back","Neck Pain","Radiculopathy Multiple Sites","Spinal Stenosis Cervicothoracic Region","Spinal Stenosis Lumbar","Failed Back Surgery Syndrome (FBSS)","Sciatica","Intervertebral Disc Disorders With Radiculopathy, Lumbar Region","Spine Osteoarthritis",[37,38,39,40,41],"epidural steroid injections","back pain treatments","pain relief","spinal steroid injections","spinal injections","RECRUITING","2026-08-07",{"date":45,"type":46},"2026-08-13","ACTUAL",{"date":48,"type":46},"2026-07-30",{"date":50,"type":21},"2030-03",{"name":52,"class":53},"Igor Wilderman. MD","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100639545","efficacy-of-cognitive-functional-therapy-in-individuals-with-chronic-low-back-pain-after-spinal-surgery-100639545","NCT07576062","Efficacy of Cognitive Functional Therapy in Individuals With Chronic Low Back Pain After Spinal Surgery","Efficacy of Cognitive Functional Therapy in Individuals With Chronic Low Back Pain After Spinal Surgery: A Randomized, Sham-Controlled Trial","Inclusion Criteria:\n\n* Age 18-75 years\n* Chronic low back pain ≥12 weeks\n* History of lumbar surgery ≥3 months\n* Pain intensity ≥3 (NPRS)\n* ODI ≥14%\n\nExclusion Criteria:\n\n* Serious spinal pathology\n* Neurological disorders\n* Radiculopathy\n* Pregnancy\n* Unstable cardiac conditions","75 Years",{"count":64,"type":21},90,[66],"NA","Chronic low back pain after spinal surgery is a complex and disabling condition influenced by biopsychosocial factors. Cognitive Functional Therapy (CFT) is a promising intervention targeting these multidimensional aspects. This randomized, sham-controlled trial aims to compare the efficacy of CFT versus a sham intervention (detuned photobiomodulation) in participants with chronic low back pain after spinal surgery.",[69,70,32],"Chronic Low Back Pain","After Lumbar Spine Surgery",[72,73,74,75,76,77,78,79,80],"Cognitive Functional Therapy","Spinal Surgery","Low-intensity light therapy","Placebo","Pain management","back pain","chronic pain","low back pain","Sham","NOT_YET_RECRUITING","2026-05-03",{"date":84,"type":46},"2026-05-08",{"date":86,"type":21},"2026-05",{"date":88,"type":21},"2027-11",{"name":90,"class":53},"Centro Universitário Augusto Motta",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":101,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":54},"100631586","evaluation-of-medication-tapering-on-the-sensitivity-of-the-spinal-cord-using-closed-loop-spinal-cord-stimulation-pilot-study-100631586","NCT07502612","Evaluation of Medication Tapering on the Sensitivity of the Spinal Cord Using Closed-Loop Spinal Cord Stimulation (Pilot Study)","Neurophysiological Effects of Pain Medication Reduction During Treatment With Closed-Loop Spinal Cord Stimulation: A Pilot Study","ECAP-MED Pilot","Inclusion Criteria:\n\n* Candidate for SCS and scheduled for trial with Evoke system.\n* Diagnosis of FBSS or FNSS (PSPS-T2).\n* Current use of ≥1 qualifying pain medication at or above minimum daily dose:\n* Gabapentin ≥150 mg\n* Pregabalin ≥75 mg\n* Morphine ≥40 mg\n* Hydromorphone ≥10 mg\n* Oxycodone ≥20 mg\n* Fentanyl ≥25 µg\n* Signed informed consent.\n* Age ≥18 years.\n\nExclusion Criteria:\n\n* Active disruptive psychiatric disorder or condition impacting pain perception or compliance.\n* Progressive neurological disease (MS, CIDP, progressive arachnoiditis, progressive diabetic neuropathy, brain\u002Fspinal tumor, severe spinal stenosis).\n* Coagulation disorder, platelet dysfunction, progressive vascular disease, or uncontrolled diabetes with procedural risk.\n* Active systemic or local infection.\n* Pregnancy.\n* Significant untreated addiction or substance abuse (within 6 months prior)",{"count":100,"type":21},20,"6 Months","OBSERVATIONAL","This pilot study investigates the effects of reducing pain medication including opioids and anticonvulsants, on spinal cord sensitivity during closed-loop spinal cord stimulation (SCS). Patients with Persistent Spinal Pain Syndrome Type 2 (FBSS\u002FFNSS) will undergo a standard 21-day SCS trial with the Evoke closed-loop system, followed by permanent implantation if successful. Neurophysiological responses (activation plots, conduction velocity, chronaxie, rheobase) and patient-reported outcomes (VAS, activity, sleep, medication intake) will be collected during the trial and up to 6 months after implantation. The goal is to evaluate the relationship between medication tapering and spinal cord sensitivity",[32,105,106],"Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine","Neurophysiological Sensitivity to Spinal Cord Stimulation",[108,109,110,111,112,113,114,115],"Spinal cord stimulation","Closed-loop stimulation","Evoked Compound Action Potentials (ECAPs)","Neurophysiology","Pain medication reduction","Neuromodulation","opioids","anticonvulsants","2026-03-27",{"date":118,"type":46},"2026-03-31",{"date":120,"type":46},"2022-06-08",{"date":122,"type":21},"2026-08-28",{"name":124,"class":53},"Brai²n"]